Swiss pharma giant Roche today released full-year 2024 financials, showing that group sales grew 7% at constant exchange ...

The presentation of Japanese drugmaker Takeda’s latest financial results were presented Thursday, though they took a back ...

Evaxion Biotech has priced a public offering, seeking to raise $10.8 million before expenses, with closing anticipated tomorrow.

UK health technology assessor the National Institute for Health and Care Excellence (NICE) has recommended Acarizax (12 ...

In a long-term succession plan, the board of directors at Japan’s largest drugmaker Takeda has made the decision unanimously ...

A clinical-stage biopharma company developing therapeutic product candidates for metabolic diseases, such as obesity, by ...

US pharma giant Merck & Co today revealed an early stop to the Phase III HYPERION study evaluating Winrevair (sotatercept-csrk) versus placebo (both in combination with background therapy) in recently ...

New US President Donald Trump and his administration have confirmed that lowering the cost of prescription drugs for Americans is a top priority, suggesting that they will continue the work of the ...

Cullinan Therapeutics and its partner Taiho Pharmaceutical have reported a win for zipalertinib, with the primary endpoint of a Phase IIb trial being met. The data, which include a positive safety ...

The global neuromuscular disease therapeutics market is projected to grow by $13.73 billion between 2025 and 2029, according ...

In this Expert View column, Abbas Kazimi, chief business officer of Nimbus Therapeutics, discusses the advantages of a ...

San Francsiscan liver specialist 89bio (Nasdaq: ETNB) has secured $250 million through a public stock offering, following a ...